Polypill-based therapy likely to reduce ethnic inequities in use of cardiovascular preventive medications: Findings from a pragmatic randomised controlled trial

European Journal of Preventive Cardiology

Volumn 23, Issue 14, 2016, Pages 1537-1545

  Selak, Vanessa ^a   Harwood, Matire ^a   Raina Elley, C ^a   Bullen, Chris ^a   Wadham, Angela ^a   Parag, Varsha ^a   Rafter, Natasha ^a,b   Arroll, Bruce ^a   Bramley, Dale ^c   Crengle, Sue ^d  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

^d Invercargill Medical Centre   (New Zealand)

Author keywords

Cardiovascular diseases; ethnic groups; healthcare disparities; polypill; secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; CHOLESTEROL; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; CARDIOVASCULAR AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ETHNICITY; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MAORI (PEOPLE); OPEN STUDY; POLYPHARMACY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DRUG COMBINATION; EPIDEMIOLOGY; ETHNIC GROUP; ETHNOLOGY; MIDDLE AGED; MORBIDITY; MULTICENTER STUDY; NEW ZEALAND; RETROSPECTIVE STUDY; RISK ASSESSMENT; TIME FACTOR; TRENDS;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; ETHNIC GROUPS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MORBIDITY; NEW ZEALAND; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84984908026     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487316637196     Document Type: Article

References (35)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
2. World Health Organization. Global Health Estimates 2014 Summary Tables: DALY by Cause, Age and Sex, 2000-2012, Geneva: World Health Organization, 2014.
3. Mendis S, Puska P, Norrving B,. Global Atlas on Cardiovascular Disease Prevention and Control, Geneva: World Health Organization, 2011.
4. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): A prospective epidemiological survey. Lancet 2011; 378: 1231-1243.
5. World Health Organization. Secondary Prevention of Non-Communicable Disease in Low and Middle Income Countries through Community-Based and Health Service Interventions-Wellcome Trust Meeting Report 1-3 August 2001, Geneva: World Health Organization, 2002.
6. Yusuf S,. Two decades of progress in preventing vascular disease. Lancet 2002; 360: 2-3.
7. Wald NJ, Law MR,. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419-1424.
8. Soliman EZ, Mendis S, Dissanayake WP, et al. A polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization. Trials 2011; 12: 3-3.
9. Zamorano J, Erdine S, Pavia A, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: The CRUCIAL trial. Curr Med Res Opin 2011; 27: 821-833.
10. Thom S, Poulter NR, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD. The UMPIRE randomised clinical trial. JAMA 2013; 310: 918-929.
11. Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 2015; 22: 920-930.
12. Selak V, Elley C, Bullen C, et al. Effect of fixed dose combination therapy on adherence and risk factor control among patients at high risk of cardiovascular disease: Randomised controlled trial in primary care. BMJ 2014; 348: g3318-g3318.
13. Statistics New Zealand. 2013 Census-major ethnic groups in New Zealand. Available from: http://www.stats.govt.nz/Census/2013-census/profile-and-summary-reports/infographic-culture-identity.aspx (2014; accessed 5 December 2014).
14. Ministry of Health. Mortality and Demographic Data 2010, Wellington: Ministry of Health, 2013.
15. Chan WC, Wright C, Riddell T, et al. Ethnic and socioeconomic disparities in the prevalence of cardiovascualar disease in New Zealand. N Z Med J 2008; 121: 11-20.
16. Ministry of Health. Annual Update of Key Results 2013/14: New Zealand Health Survey, Wellington: Ministry of Health, 2014.
17. Blakely T, Tobias M, Robson B, et al. Widening ethnic mortality disparities in New Zealand 1981-99. Soc Sci Med 2005; 61: 2233-2251.
18. MacPherson L,. New Zealand Period Life Tables: 2012-14, Wellington: Statistics New Zealand, 2015.
19. New Zealand Guidelines Group. New Zealand Cardiovascular Guidelines Handbook, Wellington: New Zealand Guidelines Group, 2009.
20. New Zealand Guidelines Group. New Zealand Primary Care Handbook 2012, Wellington: New Zealand Guidelines Group, 2012.
21. University of Auckland, Health Quality & Safety Commission. Cardiovascular outcomes. Health Quality & Safety Commission Atlas of Healthcare Variation, 2012. Available at: http://www.hqsc.govt.nz/our-programmes/health-quality-evaluation/projects/atlas-of-healthcare-variation/cardiovascular-disease/ (accessed 3 December 2012).
22. Bramley D, Riddell T, Crengle S, et al. A call to action on Maori cardiovascular health. N Z Med J 2004; 117: U957-U957.
23. Robson B. Mana Whakamarama-Equal Explanatory Power: Maori and non-Maori Sample Size in National Health Surveys. Wellington: Te Ropu Rangahau Hauora a Eru Pomare, Wellington School of Medicine and Health Sciences, University of Otago for Public Health Intelligence, Ministry of Health, New Zealand, 2002.
24. Selak V, Elley C, Crengle S, et al. Improving adherence using combination therapy (IMPACT): Design and protocol of a randomised controlled trial in primary care. Contemp Clin Trials 2011; 32: 909-915.
25. Anderson KM, Odell PM, Wilson PWF, et al. Cardiovascular disease risk profiles. Am Heart J 1990; 121: 293-298.
26. New Zealand Guidelines Group. Evidence-Based Best Practice Guideline. The Assessment and Management of Cardiovascular Risk. Wellington: New Zealand Guidelines Group, 2003.
27. Ni Mhurchu C, Blakely T, Funaki-Tahifote M, et al. Inclusion of indigenous and ethnic minority populations in intervention trials: Challenges and strategies in a New Zealand supermarket study. J Epidemiol Community Health 2009; 63: 850-855.
28. Sibthorpe B, Bailie RS, Brady MA, et al. The demise of a planned randomised controlled trial in an urban Aboriginal medical service. Med J Aust 2002; 176: 273-276.
29. Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic review. Cancer 2007; 111: 228-242.
30. Selak V, Crengle S, Elley C, et al. Recruiting equal numbers of indigenous and non-indigenous participants to a 'polypill' randomized trial. Int J Equity Health 2013; 12: 44-44.
31. International Conference on Harmonisation Expert Working Group. Guideline for Good Clinical Practice E6(R1), Geneva: International Conference on Harmonisation, 1996.
32. National Ethics Advisory Committee. Ethical Guidelines for Intervention Studies: Revised Edition, Wellington: Ministry of Health, 2012.
33. Medsafe (New Zealand Medicines and Medical Devices Safety Authority). New Zealand Regulatory Guidelines for Medicines. Volume 3: Interim Good Clinical Research Practice Guideline, Wellington: Ministry of Health, 1998.
34. Law MR, Morris JK, Wald NJ,. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665-b1665.
35. Laba T-L, Hayes A, Lo S, et al. An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. Med J Aust 2014; 11: 671-673.